Biocon Expects ‘Successful’ US Trastuzumab Launch Despite Amgen Debut

India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.

Spacecraft
With Rocketing Profits, Biocon Is Looking Forward To A Successful Launch • Source: Shutterstock

Biocon reported that its financial first-quarter net profit rocketed by 72% and forecast a strong full-year performance as it insisted that its future US trastuzumab launch will be “very successful” despite the surprise early market debut of Amgen’s rival biosimilar.

Amgen’s launch on 19 July of Kanjinti, a generic of Roche’s blockbuster breast-cancer drug Herceptin, means Biocon and partner...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.